Chemotherapy and radiotherapy: cryptic anticancer vaccines - PubMed (original) (raw)

Review

doi: 10.1016/j.smim.2010.03.001. Epub 2010 Apr 18.

Oliver Kepp, François Ghiringhelli, Lionel Apetoh, Laetitia Aymeric, Clara Locher, Antoine Tesniere, Isabelle Martins, André Ly, Nicole M Haynes, Mark J Smyth, Guido Kroemer, Laurence Zitvogel

Affiliations

Review

Chemotherapy and radiotherapy: cryptic anticancer vaccines

Yuting Ma et al. Semin Immunol. 2010 Jun.

Abstract

An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger "danger signals" emitted from immunogenic cell death and hence elicit "danger associated molecular patterns" to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of "immunogenic chemotherapy" at the levels of the drug, of the tumor cell and of the host immune system.

Copyright 2010 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources